Cargando…
Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.
In a consecutive series of studies, 164 patients with symptomatic and/or visceral metastatic malignant melanoma were treated with single agent vindesine, high dose melphalan with autologous bone marrow transplantation (AMBT), high dose BCNU with ABMT or the BOLD (bleomycin, vincristine, CCNU and DTI...
Autores principales: | Lakhani, S., Selby, P., Bliss, J. M., Perren, T. J., Gore, M. E., McElwain, T. J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1990
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971420/ https://www.ncbi.nlm.nih.gov/pubmed/1690022 |
Ejemplares similares
-
Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease.
por: Perren, T. J., et al.
Publicado: (1990) -
High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.
por: Zulian, G. B., et al.
Publicado: (1989) -
Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.
por: Currie, G. A., et al.
Publicado: (1975) -
High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.
por: Mbidde, E. K., et al.
Publicado: (1988) -
Colony growth and clonogenic cell survival in human melanoma xenografts treated with chemotherapy.
por: Selby, P. J., et al.
Publicado: (1980)